2025年1至6月份，天康生物的营业收入构成为：生猪养殖占比32.2%，饲料占比27.51%，农产品加工占 比16.37%，玉米收储行业占比14.75%，兽药占比5.44%。 截至发稿，天康生物市值为98亿元。 每经AI快讯，天康生物（SZ 002100，收盘价：7.17元）11月27日晚间发布公告称，天康生物股份有限 公司（以下简称"公司"）董事会于近日收到公司董事、总经理成辉先生的书面辞职报告，其原定总经理 任期至第八届董事会届满之日止,因成辉先生已临近法定退休年龄,申请辞去公司总经理职务。辞职后， 成辉先生仍继续担任公司第八届董事会董事、战略与投资委员会委员职务。公司董事会同意聘任许衡先 生为公司总经理。 每经头条（nbdtoutiao）——灌水21万亿，高市早苗1.7万亿强化国防！日本负债率已远超债务危机时的 希腊，对美巨额投资致大规模资本外流，"卖出日元成国际趋势" （记者 曾健辉） ...

蔚蓝生物（603739）(603739.SH)公告，公司及全资子公司青岛康地恩动物药业有限公司与其他单位联 合申报的"氧化胺碘溶液"获批准为三类新兽药，近日已获核发《新兽药注册证书》。 ...

智通财经APP讯，蔚蓝生物(603739.SH)公告，公司及全资子公司青岛康地恩动物药业有限公司与其他 单位联合申报的"氧化胺碘溶液"获批准为三类新兽药，近日已获核发《新兽药注册证书》。 ...

2025年11月27日，*ST绿康（sz002868）触及涨停，涨停价46.06元，涨幅4.99%，总市值71.58亿元，流 通市值70.95亿元，截止发稿，总成交额2296.60万元。 声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 根据喜娜AI异动分析，*ST绿康涨停原因可能如下，资产重组+控制权变更+财务优化： 1、2025年公司 处于战略转型关键期，11月26日公司以现金交易方式出售三家亏损光伏子公司股权，有效剥离亏损资 产，改善合并报表质量。同时福建纵腾网络成为新控股股东，有望带来新资源推动公司发展。资产出售 后公司资产负债率显著下降，还获得1.5亿元无担保借款用于日常经营，财务状况得以优化。 2、公司原 本主业为兽药 ...

对此，有业内人士分析认为，交易完成意味着该公司亏损光伏业务资产被剥离置出，此举将有助于改善 公司未来财务状况。 随着原控股股东的退出，新晋控股股东纵腾网络也引发市场关注。公开信息显示，纵腾网络成立于2009 年，以"全球跨境电商基础设施服务商"为企业定位，聚焦跨境仓储与物流，为全球跨境电商商户、出口 贸易企业、出海品牌商提供海外仓储、商业专线物流、定制化物流等一体化物流解决方案，旗下拥有谷 仓海外仓、云途物流、WORLDTECH等品牌。财务数据显示，2024年度，纵腾网络营业总收入271.05 亿元，净利润11.22亿元，公司总资产104.43亿元，总负债48亿元。 11月26日，《证券日报》记者致电*ST绿康拟进一步了解新控股股东等情况，公司工作人员回复称，以 公司公告披露为准。 由于公司2024年末经审计的归属于上市公司股东的净资产为负值、最近连续三个会计年度扣除非经常性 损益前后净利润均为负值，且2024年被出具"与持续经营相关的重大不确定性部分"的审计意见，根据 《深圳证券交易所股票上市规则》的规定，公司股票交易被实施"退市风险警示"及"其他风险警示"。 在此背景下，上市公司原控股股东方开始筹划控制权 ...

2025年1至6月份，*ST绿康的营业收入构成为：兽药占比61.79%，光伏胶膜占比26.1%，生物农药占比 5.99%，其他占比2.83%，食品添加剂占比2.19%。 截至发稿，*ST绿康市值为62亿元。 每经AI快讯，*ST绿康（SZ 002868，收盘价：39.79元）11月24日晚间发布公告称，公司于2025年11月 24日收到康怡投资等股份转让方的通知，其与纵腾网络股份转让相关过户登记手续已于2025年11月21日 办理完成，并已取得中国证券登记结算有限责任公司出具的《证券过户登记确认书》。本次股份转让完 成后，纵腾网络持有上市公司股份约4661万股，占公司总股本的29.99%，公司控股股东由康怡投资变 更为纵腾网络，实际控制人由赖潭平变更为王钻。 每经头条（nbdtoutiao）——大鹏工业战略配售"肥"了自家人！认购价9元，上市首日涨到118元，实控 人和亲哥哥凭配售一天浮盈2492万元 （记者 曾健辉） ...

值得一提的是，此次入主*ST绿康，也系王钻的首个上市平台。 （文章来源：北京商报） 北京商报讯11月24日晚间，*ST绿康（002868）披露公告称，公司股东协议转让过户完成，公司控股股 东由上海康怡投资有限公司（以下简称"康怡投资"）变更为福建纵腾网络有限公司（以下简称"纵腾网 络"），实际控制人由赖潭平变更为王钻。 公告显示，*ST绿康于当日收到康怡投资等股份转让方的通知，其与纵腾网络股份转让相关证券过户登 记手续已于11月21日办理完成，纵腾网络持有上市公司股份4660.84万股，占公司总股本的29.99%。 从业务方面看，*ST绿康是一家专注于兽药研发、生产和销售的高新技术企业，2023年公司完成收购绿 康玉山并设立绿康海宁，启动光伏胶膜项目投资建设，形成"动保产品+光伏胶膜产品"生产和销售的双 主业的发展模式。纵腾网络则以"全球跨境电商基础设施服务商"为企业定位，聚焦跨境仓储与物流，为 全球跨境电商商户、出口贸易企业、出海品牌商提供海外仓储、商业专线物流、定制化物流等一体化物 流解决方案。 ...

Core Viewpoint - On November 20, 2023, the stock of Pulaike experienced a decline of 0.58%, with a trading volume of 43.79 million yuan, indicating a negative trend in market performance [1] Financing Summary - On the same day, Pulaike had a financing buy-in amount of 4.09 million yuan and a financing repayment of 12.67 million yuan, resulting in a net financing outflow of 8.58 million yuan [1] - As of November 20, the total financing and securities lending balance for Pulaike was 135 million yuan, which is 2.82% of its circulating market value, indicating a low financing balance compared to the past year [1] - The company repaid 100 shares of securities lending and sold 700 shares, with a selling amount of 9,674 yuan, while the remaining securities lending volume was 25,700 shares, with a balance of 355,200 yuan, which is above the 50th percentile of the past year [1] Company Overview - Pulaike Bioengineering Co., Ltd. was established on June 22, 2002, and listed on May 18, 2015, primarily engaged in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2] - The revenue composition includes poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2] - As of September 30, 2023, the number of shareholders was 16,700, a decrease of 7.26%, while the average circulating shares per person increased by 7.83% to 20,739 shares [2] Financial Performance - For the period from January to September 2023, Pulaike achieved an operating income of 823 million yuan, representing a year-on-year growth of 8.04%, and a net profit attributable to shareholders of 157 million yuan, reflecting a significant increase of 47.86% [2] Dividend Information - Since its A-share listing, Pulaike has distributed a total of 1.125 billion yuan in dividends, with 568 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2023, the sixth largest circulating shareholder was the Guotai Zhongzheng Livestock Breeding ETF, holding 5.4716 million shares, an increase of 2.0217 million shares from the previous period [3] - The Hong Kong Central Clearing Limited was the eighth largest circulating shareholder, holding 3.832 million shares as a new shareholder [3]

Investment Rating - The report maintains a "Buy" rating for Jinhe Biological (002688) with a target price not specified [1]. Core Views - The company reported a revenue of 2.036 billion yuan for the first three quarters of 2025, a year-on-year increase of 22.86%, and a net profit attributable to shareholders of 139 million yuan, up 22.25% year-on-year [2]. - In Q3 2025, the company achieved a revenue of 646 million yuan, a 9.20% increase year-on-year, but the net profit dropped to 1.15 million yuan, a decline of 94.94% year-on-year [2][3]. - The decline in Q3 profit is attributed to increased marketing efforts, higher employee compensation, and increased R&D expenses [3]. - The main product, Jinmeisu, has seen a cost reduction, and both domestic and international sales are performing well [4]. - The company is actively expanding its pet business, focusing on pharmaceuticals and vaccines, with a dual-brand strategy for domestic and international markets [5]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 2.036 billion yuan, a 22.86% increase year-on-year, and a net profit of 139 million yuan, up 22.25% year-on-year [2]. - In Q3 2025, revenue was 646 million yuan, a 9.20% increase year-on-year, while net profit fell to 1.15 million yuan, a 94.94% decline year-on-year [2][3]. Market and Product Analysis - The sales of the main product, Jinmeisu, have increased significantly, with growth in both domestic and international markets [4]. - The company has adjusted the cost of Jinmeisu downwards, benefiting from lower raw material prices and increased production capacity [4]. - The pet business is a key strategic focus, with plans to develop a range of pharmaceutical and vaccine products [5]. Future Outlook - The company forecasts revenue for 2025-2027 to be 2.835 billion, 3.030 billion, and 3.274 billion yuan respectively, with net profits projected at 197 million, 326 million, and 423 million yuan [7]. - The report highlights the potential for growth in the pet market, which is expected to exceed 300 billion yuan in 2024 [5].

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Product Approval - The approved products include Compound Streptomycin Ointment, which is used to treat otitis externa in dogs and cats caused by bacteria sensitive to neomycin, fungi sensitive to streptomycin, and ear mites sensitive to chlorpyrifos [1] - The second product, Tocilizumab Suspension, is intended for the prevention of coccidiosis in piglets and calves [1] Strategic Implications - The approval of these veterinary drug products will enrich the company's veterinary medicine product line and structure, facilitating its strategic layout in the veterinary drug sector [1] - This development is expected to enhance the company's market competitiveness within the veterinary medicine industry [1]